Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OPTIMAL DURATION OF CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER - A RANDOMIZED STUDY OF 4 VERSUS 6 CYCLES OF CISPLATIN-ETOPOSIDE
Autore:
VESLEMES M; POLYZOS A; LATSI P; DIMITROULIS J; STAMATIADIS D; DARDOUFAS C; RASIDAKIS A; KATSILAMBROS N; JORDANOGLOU J;
Indirizzi:
UNIV ATHENS,SCH MED,DEPT PROPEDEUT MED 1,LAIKON HOSP GR-11527 ATHENS GREECE UNIV ATHENS,SCH MED,DEPT PROPEDEUT MED 1,LAIKON HOSP GR-11527 ATHENS GREECE
Titolo Testata:
Journal of chemotherapy
fascicolo: 2, volume: 10, anno: 1998,
pagine: 136 - 140
SICI:
1120-009X(1998)10:2<136:ODOCIS>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-III; TRIAL; MAINTENANCE;
Keywords:
SMALL CELL LUNG CANCER; DURATION OF TREATMENT; ETOPOSIDE-CISPLATIN; LUNG CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
12
Recensione:
Indirizzi per estratti:
Citazione:
M. Veslemes et al., "OPTIMAL DURATION OF CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER - A RANDOMIZED STUDY OF 4 VERSUS 6 CYCLES OF CISPLATIN-ETOPOSIDE", Journal of chemotherapy, 10(2), 1998, pp. 136-140

Abstract

With the purpose of investigating whether the 6-course standard dose treatment of etoposide-platinum (EP) in small cell lung cancer could be reduced to 4 courses without compromising patient's survival, 70 patients were randomized to receive either 4 or 6 cycles of etoposide 120mg/m(2) i.v. days 1-3 and cisplatin 80 mg/m(2) day 1, With the intention of comparing these two durations as primary treatment policies, patients were randomized on admission and not after the fourth course. From the 69 evaluable patients 34 received EPx4 cycles and 35 EPx6 cycles. Objective response for EPx4 was achieved by 21 patients (62%, 95% CI 44%-78%) compared to 24 patients (69%, 95% CI 51%-83%) of the EPx6 group, Median times to progression were 6 mo (4-19) and 7 mo (4-40) respectively (P=0.06) in the two groups. Median survivals were 8.5 mo (4-28.5) and 9.5 mo (4-51) (p=0.04) respectively. No differences in the survival of limited-disease patients were shown with 10.5 mo (6-28.5) and 12 mo (8-51) respectively, in the two groups. Patients with extensive disease had a trend favoring prolonged chemotherapy with a median survival of 9 mo (5-16) versus 6.5 mo (4-16.5) for those in the EPx4 group (p=0.09). Toxicity was not significantly more severe in the EPx6 group. In conclusion, patients achieving complete response within 4 cycles may not need continued chemotherapy, but patients with extensive disease may benefit from 2 more cycles.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 08:39:49